Ayad K. Abdul-Ahad
BOTh Analytics GmbH, Germany
Title: The BURDEN OF THERAPY©* [BOTh©*]. A novel method to evaluate the impact of therapeutic agents on patient safety
Biography
Biography: Ayad K. Abdul-Ahad
Abstract
BOTh analyzes daily patient safety on a clinical study. It provides a more accurate reflection of the burden of treatment than current safety methods and facilitate informed treatment selection. Patient-level safety data was utilized to quantify the daily burden of adverse events by severity on a per patient and per day basis, and presented using a chart. Data from two published studies in peripheral neuropathic pain (PNP) and overactive bladder (OAB) were utilized. In the PNP study, the overall BOTh graph showed a difference in AEs in the two treatment groups.The topical TRPV1 agonist group showed an initial peak followed by a rapid decline in AEs per day, due primarily to transient application site reactions.The oral anticonvulsant group, showed a gradual increase, followed by a consistent number of AEs to the the study end. The overall burden (area under the curve) was 61.2 for the oral anticonvulsant and 23.5 for the topical TRPV1 agonist (p<0.0001).The integration of safety and efficacy into the graph allowed the safety burden comparison with the median time to treatment response. In the OAB study, the overall burden were similar between the two groups. An analysis of patients with dry mouth revealed that more patients reported it in the antimuscarinic group p=0.02. BOTh provides visual representation and statistical analyses of the burden of medication in individual patients or subgroups combining tolerability and efficacy. BOTh allows sensitive, clinically relevant analysis than current methods, which show an overall summary not reporting pateints with more than one AE over time.